Skip to content
Screener

Cerus CERS Gross Profit

Gross Profit at other companies

Haemonetics logo
HaemoneticsHAE
$202.8M+5.5%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$309.4M+1.1%
QuidelOrtho Corporation logo
QuidelOrtho CorporationQDEL
$272.9M-0.7%
ADMA Biologics logo
ADMA BiologicsADMA
$86.28M+28.3%
Paysign logo
PaysignPAYS
$17.9M+52.2%

Other financials

Income statement

See full
Revenue$53.7M+24.1%
Operating income-$354.0K+94.0%
Net income-$1.6M+78.7%
EPS (diluted)-$0.01+75.0%

Balance sheet

See full
Cash & equivalents$27.9M+43.0%
Total debt$45.0M-43.3%
Total equity$67.6M+21.7%
Total assets$222.9M+7.8%

Cash flow

See full
Operating cash flow-$3.0M-261%
CapEx$233.0K+108%
Free cash flow-$3.3M-243%

Valuation

See full
Market cap$473.58M+119%
Enterprise value$490.69M+83.1%
P/S2.4×-0.8×

Profitability

See full
Gross margin64%
Operating margin-6.2%-2.1pp
Net margin-9.8%-2.8pp
FCF margin3.5%+1.9pp

Returns & leverage

See full
Return on equity-15.5%-5.6pp
Debt / equity0.7×-0.8×
Current ratio1.6×-0.7×

Where this comes from

Calculated from Cerus’s reported figures.

The source filing: Cerus’s 10-K, filed March 1, 2023.

Filed
Mar 1, 2023
Fiscal year
FY2022
Accession
0000950170-23-005558
Line itemYear Ended December 31, 2022Year Ended December 31, 2021Year Ended December 31, 2020
Product revenue$162,048$130,859$91,920
Cost of product revenue74,95463,47541,157
Gross profit on product revenue87,09467,38450,763
Government contract revenue26,26728,65922,329
Operating expenses:
Research and development64,10763,69164,410
Selling, general and administrative83,33581,28867,015
Total operating expenses147,442144,979131,425

Item 16. Form 10-K Summary

FAQ

What does gross profit mean?
Revenue minus cost of revenue — the profit available to cover operating expenses, representing the company's pricing power and production efficiency.